{"data_date":"2026-11-08","library_size":29380,"matched_against":"each record's title and abstract (summary field), case-insensitive","n":166,"page":"https://alzhub.org/answers/donanemab","query":"title or abstract mentions \"donanemab\", \"Kisunla\" or \"LY3002813\"","studies":[{"alzhub_score":15,"alzhub_url":"https://alzhub.org/study/fda-approves-treatment-for-adults-with-alzheimer-s-disease-kisunla-7f8e71c0","doi":null,"journal":"U.S. Food and Drug Administration","n_participants":null,"pmid":null,"source_url":"https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease","study_design":"regulatory decision","title":"FDA Approves Treatment for Adults with Alzheimer's Disease (Kisunla / donanemab-azbt)","title_match":true,"year":2024},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/donanemab-in-early-symptomatic-alzheimer-disease-the-trailblazer-alz-9857475c","doi":null,"journal":"JAMA","n_participants":1736,"pmid":null,"source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10352931/","study_design":"phase-3-trial","title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","title_match":true,"year":2023},{"alzhub_score":15,"alzhub_url":"https://alzhub.org/study/kisunla-donanemab-eu-marketing-authorization-epar-following-chmp-re-87b2f0ae","doi":null,"journal":"European Medicines Agency","n_participants":null,"pmid":null,"source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/kisunla","study_design":"regulatory decision","title":"Kisunla (donanemab) \u2014 EU Marketing Authorization (EPAR), following CHMP re-examination","title_match":true,"year":2025},{"alzhub_score":10,"alzhub_url":"https://alzhub.org/study/national-coverage-determination-monoclonal-antibodies-directed-ff44148a","doi":null,"journal":"Centers for Medicare & Medicaid Services","n_participants":null,"pmid":null,"source_url":"https://www.cms.gov/medicare/coverage/coverage-evidence-development/monoclonal-antibodies-directed-against-amyloid-treatment-alzheimers-disease-ad","study_design":"coverage determination","title":"National Coverage Determination: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (NCD 200.3)","title_match":false,"year":2022},{"alzhub_score":69,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-in-anti-amyloid-therapies-912127c4","doi":null,"journal":"Alzheimer's & Dementia","n_participants":null,"pmid":null,"source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13099593/","study_design":"systematic-review","title":"Amyloid-Related Imaging Abnormalities (ARIA) in Anti-Amyloid Therapies for Alzheimer's Disease: An Update from the Alzheimer's Association ARIA Workgroup","title_match":false,"year":2026},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/cost-effectiveness-of-aducanumab-and-donanemab-for-early-alzheimer-b0c356d3","doi":null,"journal":"JAMA Neurology","n_participants":null,"pmid":null,"source_url":"https://jamanetwork.com/journals/jamaneurology/fullarticle/2790531","study_design":"modelling","title":"Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US","title_match":true,"year":2022},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-with-donanemab-in-early-40063015","doi":"10.1001/jamaneurol.2025.0065","journal":"JAMA Neurology","n_participants":3030,"pmid":"40063015","source_url":"https://pubmed.ncbi.nlm.nih.gov/40063015/","study_design":"phase-3-trial","title":"Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials","title_match":true,"year":2025},{"alzhub_score":76,"alzhub_url":"https://alzhub.org/study/modified-titration-of-donanemab-reduces-aria-risk-and-maintains-40172303","doi":"10.1002/alz.70062","journal":"Alzheimer's & Dementia","n_participants":843,"pmid":"40172303","source_url":"https://pubmed.ncbi.nlm.nih.gov/40172303/","study_design":"phase-3-trial","title":"Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction","title_match":true,"year":2025},{"alzhub_score":63,"alzhub_url":"https://alzhub.org/study/clinical-meaningfulness-of-donanemab-in-early-symptomatic-alzheimer-42128444","doi":"10.1212/CPJ.0000000000200621","journal":"Neurology: Clinical Practice","n_participants":null,"pmid":"42128444","source_url":"https://pubmed.ncbi.nlm.nih.gov/42128444/","study_design":"phase-3-trial","title":"Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial","title_match":true,"year":2026},{"alzhub_score":54,"alzhub_url":"https://alzhub.org/study/plasma-p-tau217-for-detecting-amyloid-clearance-after-donanemab-in-42565262","doi":"10.1002/alz.71740","journal":"Alzheimer's & Dementia","n_participants":830,"pmid":"42565262","source_url":"https://pubmed.ncbi.nlm.nih.gov/42565262/","study_design":"phase-3-trial","title":"Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease","title_match":true,"year":2026},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/clinically-important-benefits-and-harms-of-monoclonal-antibodies-38253509","doi":"10.1370/afm.3050","journal":"Annals of Family Medicine","n_participants":23202,"pmid":"38253509","source_url":"https://pubmed.ncbi.nlm.nih.gov/38253509/","study_design":"meta-analysis","title":"Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis","title_match":false,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/cost-effectiveness-of-donanemab-for-early-alzheimer-disease-in-42015793","doi":"10.5694/mja2.70186","journal":"The Medical journal of Australia","n_participants":null,"pmid":"42015793","source_url":"https://pubmed.ncbi.nlm.nih.gov/42015793/","study_design":"modelling","title":"Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia","title_match":true,"year":2026},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/value-based-prices-of-emerging-disease-modifying-therapies-for-42125995","doi":"10.1002/alz.71308","journal":"Alzheimer's & Dementia","n_participants":null,"pmid":"42125995","source_url":"https://pubmed.ncbi.nlm.nih.gov/42125995/","study_design":"modelling","title":"Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis","title_match":false,"year":2026},{"alzhub_score":49,"alzhub_url":"https://alzhub.org/study/cost-effectiveness-of-traditional-and-novel-neurotherapeutic-agents-41837605","doi":"10.1177/13872877261430376","journal":"Journal of Alzheimer's Disease","n_participants":null,"pmid":"41837605","source_url":"https://pubmed.ncbi.nlm.nih.gov/41837605/","study_design":"systematic-review","title":"Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review","title_match":false,"year":2026},{"alzhub_score":82,"alzhub_url":"https://alzhub.org/study/association-of-donanemab-treatment-with-exploratory-plasma-biomarkers-36251300","doi":"10.1001/jamaneurol.2022.3392","journal":"JAMA neurology","n_participants":1955,"pmid":"36251300","source_url":"https://pubmed.ncbi.nlm.nih.gov/36251300/","study_design":null,"title":"Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial","title_match":true,"year":2022},{"alzhub_score":76,"alzhub_url":"https://alzhub.org/study/posttreatment-amyloid-levels-and-clinical-outcomes-following-41082199","doi":"10.1001/jamaneurol.2025.3869","journal":"JAMA neurology","n_participants":1582,"pmid":"41082199","source_url":"https://pubmed.ncbi.nlm.nih.gov/41082199/","study_design":"clinical trial","title":"Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial","title_match":true,"year":2025},{"alzhub_score":42,"alzhub_url":"https://alzhub.org/study/advanced-brain-imaging-for-the-diagnosis-of-alzheimer-disease-37639461","doi":"10.1097/wco.0000000000001198","journal":"Current opinion in neurology","n_participants":null,"pmid":"37639461","source_url":"https://pubmed.ncbi.nlm.nih.gov/37639461/","study_design":null,"title":"Advanced brain imaging for the diagnosis of Alzheimer disease","title_match":false,"year":2023},{"alzhub_score":76,"alzhub_url":"https://alzhub.org/study/association-of-amyloid-reduction-after-donanemab-treatment-with-tau-36094645","doi":"10.1001/jamaneurol.2022.2793","journal":"JAMA neurology","n_participants":272,"pmid":"36094645","source_url":"https://pubmed.ncbi.nlm.nih.gov/36094645/","study_design":"clinical trial","title":"Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial","title_match":true,"year":2022},{"alzhub_score":60,"alzhub_url":"https://alzhub.org/study/tracking-neuroinflammatory-biomarkers-in-alzheimer-s-disease-a-39080712","doi":"10.1186/s12974-024-03163-y","journal":"Journal of neuroinflammation","n_participants":null,"pmid":"39080712","source_url":"https://pubmed.ncbi.nlm.nih.gov/39080712/","study_design":"longitudinal study","title":"Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?","title_match":false,"year":2024},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/donanemab-in-early-symptomatic-alzheimer-disease-the-trailblazer-alz-37459141","doi":"10.1001/jama.2023.13239","journal":"JAMA","n_participants":860,"pmid":"37459141","source_url":"https://pubmed.ncbi.nlm.nih.gov/37459141/","study_design":"clinical trial","title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","title_match":true,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/targeting-amyloid-pathology-in-early-alzheimer-s-the-promise-of-39998021","doi":"10.3390/pharmacy13010023","journal":"Pharmacy (Basel, Switzerland)","n_participants":null,"pmid":"39998021","source_url":"https://pubmed.ncbi.nlm.nih.gov/39998021/","study_design":"clinical trial","title":"Targeting Amyloid Pathology in Early Alzheimer's: The Promise of Donanemab-Azbt","title_match":true,"year":2025},{"alzhub_score":52,"alzhub_url":"https://alzhub.org/study/comparison-of-the-efficacy-of-updated-drugs-for-the-treatment-on-the-39550061","doi":"10.1016/j.neuroscience.2024.11.029","journal":"Neuroscience","n_participants":null,"pmid":"39550061","source_url":"https://pubmed.ncbi.nlm.nih.gov/39550061/","study_design":"meta-analysis","title":"Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer 's disease: A systematic review and network meta- analysis","title_match":false,"year":2025},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-with-anti-amyloid-antibodies-35401412","doi":"10.3389/fneur.2022.862369","journal":"Frontiers in neurology","n_participants":null,"pmid":"35401412","source_url":"https://pubmed.ncbi.nlm.nih.gov/35401412/","study_design":null,"title":"Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease","title_match":false,"year":2022},{"alzhub_score":54,"alzhub_url":"https://alzhub.org/study/cost-effectiveness-of-aducanumab-and-donanemab-for-early-alzheimer-35344024","doi":"10.1001/jamaneurol.2022.0315","journal":"JAMA neurology","n_participants":null,"pmid":"35344024","source_url":"https://pubmed.ncbi.nlm.nih.gov/35344024/","study_design":"clinical trial","title":"Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US","title_match":true,"year":2022},{"alzhub_score":79,"alzhub_url":"https://alzhub.org/study/donanemab-in-early-alzheimer-s-disease-33720637","doi":"10.1056/nejmoa2100708","journal":"The New England journal of medicine","n_participants":257,"pmid":"33720637","source_url":"https://pubmed.ncbi.nlm.nih.gov/33720637/","study_design":"clinical trial","title":"Donanemab in Early Alzheimer's Disease","title_match":true,"year":2021},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/new-and-emerging-drug-therapies-for-alzheimer-disease-38962384","doi":"10.18773/austprescr.2024.021","journal":"Australian prescriber","n_participants":null,"pmid":"38962384","source_url":"https://pubmed.ncbi.nlm.nih.gov/38962384/","study_design":null,"title":"New and emerging drug therapies for Alzheimer disease","title_match":false,"year":2024},{"alzhub_score":34,"alzhub_url":"https://alzhub.org/study/how-promising-are-the-latest-monoclonal-antibodies-targeting-amyloid-38193477","doi":"10.1080/14728214.2024.2304059","journal":"Expert opinion on emerging drugs","n_participants":null,"pmid":"38193477","source_url":"https://pubmed.ncbi.nlm.nih.gov/38193477/","study_design":null,"title":"How promising are the latest monoclonal antibodies targeting amyloid-\u03b2 for the treatment of early Alzheimer's disease?","title_match":false,"year":2024},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/antiamyloid-treatment-for-dementia-concerns-outweigh-hopes-40511512","doi":"10.1097/yco.0000000000001021","journal":"Current opinion in psychiatry","n_participants":null,"pmid":"40511512","source_url":"https://pubmed.ncbi.nlm.nih.gov/40511512/","study_design":null,"title":"Antiamyloid treatment for dementia: concerns outweigh hopes","title_match":false,"year":2025},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/incidence-of-amyloid-related-imaging-abnormalities-and-health-41885326","doi":"10.18553/jmcp.2026.32.4.470","journal":"Journal of managed care & specialty pharmacy","n_participants":240,"pmid":"41885326","source_url":"https://pubmed.ncbi.nlm.nih.gov/41885326/","study_design":null,"title":"Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/exploring-natural-compounds-for-alzheimer-s-disease-virtual-screening-a3b419d0","doi":"10.20944/preprints202402.0232.v1","journal":"Preprints.org","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.20944/preprints202402.0232.v1","study_design":null,"title":"Exploring Natural Compounds for Alzheimer's Disease: Virtual Screening and Docking Study with KIBRA Protein","title_match":false,"year":2024},{"alzhub_score":58,"alzhub_url":"https://alzhub.org/study/donanemab-appropriate-use-recommendations-40155270","doi":"10.1016/j.tjpad.2025.100150","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"40155270","source_url":"https://pubmed.ncbi.nlm.nih.gov/40155270/","study_design":null,"title":"Donanemab: Appropriate use recommendations","title_match":true,"year":2025},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/amyloid-pet-signal-reduction-in-prior-aria-e-regions-after-41260674","doi":"10.3174/ajnr.a9111","journal":"American Journal of Neuroradiology","n_participants":null,"pmid":"41260674","source_url":"https://pubmed.ncbi.nlm.nih.gov/41260674/","study_design":null,"title":"\u03b2-Amyloid PET Signal Reduction in Prior ARIA-E Regions after Antiamyloid Therapy for Alzheimer Disease","title_match":false,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/a-review-of-clinical-biomarker-insights-advances-in-diagnosis-and-5adb338a","doi":"10.25259/gjmpbu_38_2024","journal":"Global Journal of Medical Pharmaceutical and Biomedical Update","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.25259/gjmpbu_38_2024","study_design":null,"title":"A Review of Clinical Biomarker Insights: Advances in Diagnosis and Prognosis of Early Alzheimer","title_match":false,"year":2025},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-in-early-alzheimer-disease-42784125","doi":"10.3390/neurolint18090171","journal":"Neurology International","n_participants":null,"pmid":"42784125","source_url":"https://pubmed.ncbi.nlm.nih.gov/42784125/","study_design":"meta-analysis","title":"Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab","title_match":true,"year":2026},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/anticuerpos-monoclonales-antiamiloide-y-enfermedad-de-alzheimer-d85edb6b","doi":"10.24875/kranion.m26000124","journal":"Kranion","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.24875/kranion.m26000124","study_design":null,"title":"Anticuerpos monoclonales antiamiloide y enfermedad de Alzheimer: \u00bfestamos preparados?","title_match":false,"year":2026},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/lecanemab-aducanumab-and-donanemab-bind-the-same-human-alzheimer-41435407","doi":"10.1002/alz70855_099914","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"41435407","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12726945/","study_design":null,"title":"Lecanemab, aducanumab, and donanemab bind the same human Alzheimer disease A\u03b2 aggregates at different epitopes","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/pet-guided-assessment-of-amyloid-clearance-and-outcomes-in-a-real-42055956","doi":"10.3174/ajnr.a9387","journal":"American Journal of Neuroradiology","n_participants":15,"pmid":"42055956","source_url":"https://pubmed.ncbi.nlm.nih.gov/42055956/","study_design":"longitudinal study","title":"PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid Therapy","title_match":false,"year":2026},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/use-of-lecanemab-and-donanemab-in-the-canadian-healthcare-system-39893139","doi":"10.1016/j.tjpad.2025.100068","journal":"The Journal of Prevention of Alzheimer s Disease","n_participants":null,"pmid":"39893139","source_url":"https://pubmed.ncbi.nlm.nih.gov/39893139/","study_design":null,"title":"Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research","title_match":true,"year":2025},{"alzhub_score":30,"alzhub_url":"https://alzhub.org/study/lecanemab-en-la-enfermedad-de-alzheimer-ab04d0ab","doi":"10.22379/anc.v41i2.1938","journal":"Acta neurol\u00f3gica colombiana","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.22379/anc.v41i2.1938","study_design":null,"title":"Lecanemab en la enfermedad de Alzheimer","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/treating-alzheimer-disease-with-antiamyloid-therapiesthe-real-world-40844810","doi":"10.1001/jama.2025.14180","journal":"JAMA","n_participants":null,"pmid":"40844810","source_url":"https://pubmed.ncbi.nlm.nih.gov/40844810/","study_design":null,"title":"Treating Alzheimer Disease With Antiamyloid Therapies\u2014The Real-World Experience Grows","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/evaluating-the-cost-effectiveness-of-pharmacological-therapy-in-40435868","doi":"10.1016/j.vhri.2025.101130","journal":"Value in Health Regional Issues","n_participants":null,"pmid":"40435868","source_url":"https://pubmed.ncbi.nlm.nih.gov/40435868/","study_design":null,"title":"Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in Brazil","title_match":false,"year":2025},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/a-new-era-in-neuropharmacology-assessing-the-efficacy-and-safety-of-42084750","doi":"10.1007/s00415-026-13829-7","journal":"Journal of Neurology","n_participants":null,"pmid":"42084750","source_url":"https://pubmed.ncbi.nlm.nih.gov/42084750/","study_design":null,"title":"A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's disease","title_match":false,"year":2026},{"alzhub_score":32,"alzhub_url":"https://alzhub.org/study/both-amyloid-and-tau-assessments-are-desired-before-initiating-40108731","doi":"10.1097/rlu.0000000000005842","journal":"Clinical Nuclear Medicine","n_participants":null,"pmid":"40108731","source_url":"https://pubmed.ncbi.nlm.nih.gov/40108731/","study_design":"clinical trial","title":"Both Amyloid and Tau Assessments Are Desired Before Initiating Disease-modifying Therapy for Alzheimer Disease: Three Real-world Cases","title_match":false,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-and-amyloid-related-imaging-4ee39e2d","doi":"10.5281/zenodo.22310606","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.22310606","study_design":"narrative review","title":"Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease","title_match":false,"year":2026},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-and-amyloid-related-imaging-95d6b60f","doi":"10.5281/zenodo.22310607","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.22310607","study_design":"narrative review","title":"Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease","title_match":false,"year":2026},{"alzhub_score":29,"alzhub_url":"https://alzhub.org/study/terapias-emergentes-para-la-enfermedad-de-alzheimer-revision-3c483de3","doi":"10.61368/r.s.d.h.v6i2.661","journal":"Revista Cient\u00edfica de Salud y Desarrollo Humano","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.61368/r.s.d.h.v6i2.661","study_design":null,"title":"Terapias emergentes para la enfermedad de Alzheimer: revisi\u00f3n sistem\u00e1tica de anticuerpos anti-amiloide y mecanismos alternativos","title_match":false,"year":2025},{"alzhub_score":31,"alzhub_url":"https://alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-d453d052","doi":"10.5281/zenodo.17615265","journal":"International Journal of Science and Research Archive","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.17615265","study_design":"narrative review","title":"Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-08ace6f7","doi":"10.5281/zenodo.17615266","journal":"International Journal of Science and Research Archive","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.17615266","study_design":"narrative review","title":"Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada","title_match":true,"year":2025},{"alzhub_score":31,"alzhub_url":"https://alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-1b2f6657","doi":"10.30574/ijsra.2025.17.1.2929","journal":"International Journal of Science and Research Archive","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.30574/ijsra.2025.17.1.2929","study_design":"narrative review","title":"Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada","title_match":true,"year":2025},{"alzhub_score":44,"alzhub_url":"https://alzhub.org/study/monoclonal-antibodies-for-treatment-alzheimer-s-disease-12954b56","doi":"10.31393/reports-vnmedical-2025-29(4)-29","journal":"Reports of Vinnytsia National Medical University","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.31393/reports-vnmedical-2025-29(4)-29","study_design":"systematic review","title":"Monoclonal antibodies for treatment Alzheimer`s disease","title_match":false,"year":2025},{"alzhub_score":32,"alzhub_url":"https://alzhub.org/study/cost-effectiveness-of-donanemab-for-early-alzheimer-disease-in-91bcd677","doi":"10.26187/deakin.32142121","journal":"Deakin Research Online (Deakin University)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.26187/deakin.32142121","study_design":null,"title":"Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia","title_match":true,"year":2026},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/novel-monoclonal-antibodies-for-the-treatment-of-alzheimers-disease-4e2f63cd","doi":"10.48175/ijarsct-23077","journal":"International Journal of Advanced Research in Science Communication and Technology","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.48175/ijarsct-23077","study_design":null,"title":"Novel Monoclonal Antibodies for the Treatment of Alzheimers Disease using KISUNLA Drug","title_match":true,"year":2025},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/lecanemab-and-donanemab-combination-therapy-for-alzheimers-disease-41773886","doi":"10.1097/wad.0000000000000711","journal":"Alzheimer Disease & Associated Disorders","n_participants":null,"pmid":"41773886","source_url":"https://pubmed.ncbi.nlm.nih.gov/41773886/","study_design":null,"title":"Lecanemab and Donanemab Combination Therapy for Alzheimer\u2019s Disease-The Cocktail May Work Even Better Together","title_match":true,"year":2026},{"alzhub_score":33,"alzhub_url":"https://alzhub.org/study/anti-amyloid-treatment-in-alzheimer-disease-updated-implications-for-42688139","doi":"10.3389/fneur.2026.1889769","journal":"Frontiers in Neurology","n_participants":null,"pmid":"42688139","source_url":"https://pubmed.ncbi.nlm.nih.gov/42688139/","study_design":null,"title":"Anti-amyloid treatment in Alzheimer disease: updated implications for patients with cerebral amyloid angiopathy and other cerebrovascular conditions","title_match":false,"year":2026},{"alzhub_score":31,"alzhub_url":"https://alzhub.org/study/therapeutic-monoclonal-antibodies-targeting-amyloid-beta-in-alzheimer-0a449f11","doi":"10.1186/s13064-026-00295-0","journal":"Discover Neuroscience","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1186/s13064-026-00295-0","study_design":null,"title":"Therapeutic monoclonal antibodies targeting amyloid beta in Alzheimer disease current evidence clinical outcomes limitations and future directions","title_match":false,"year":2026},{"alzhub_score":51,"alzhub_url":"https://alzhub.org/study/assessing-the-clinical-meaningfulness-of-slowing-cdrsb-progression-39949872","doi":"10.1002/trc2.70033","journal":"Alzheimer s & Dementia Translational Research & Clinical Interventions","n_participants":282,"pmid":"39949872","source_url":"https://pubmed.ncbi.nlm.nih.gov/39949872/","study_design":null,"title":"Assessing the clinical meaningfulness of slowing CDR\u2010SB progression with disease\u2010modifying therapies for Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/transkript-zur-episode-lecanemab-52ec276c","doi":"10.69156/trx.001/2025.10.00152","journal":"EvidenzUpdate","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.69156/trx.001/2025.10.00152","study_design":null,"title":"Transkript zur Episode \u201eLecanemab\u201c","title_match":false,"year":2025},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/recomendaciones-de-uso-de-donanemab-ef1b4e53","doi":"10.22379/anc.1993","journal":"Acta neurol\u00f3gica colombiana","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.22379/anc.1993","study_design":null,"title":"Recomendaciones de uso de donanemab","title_match":true,"year":2026},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/comment-by-european-alzheimers-disease-consortium-eadc-investigators-40640062","doi":"10.1016/j.tjpad.2025.100259","journal":"The Journal of Prevention of Alzheimer s Disease","n_participants":null,"pmid":"40640062","source_url":"https://pubmed.ncbi.nlm.nih.gov/40640062/","study_design":null,"title":"Comment by European Alzheimer\u2019s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer\u2019 s disease","title_match":true,"year":2025},{"alzhub_score":51,"alzhub_url":"https://alzhub.org/study/alzheimer-s-disease-neuroimaging-initiative-two-decades-of-pioneering-39760440","doi":"10.1002/alz.14186","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"39760440","source_url":"https://pubmed.ncbi.nlm.nih.gov/39760440/","study_design":"longitudinal study","title":"Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions","title_match":false,"year":2025},{"alzhub_score":29,"alzhub_url":"https://alzhub.org/study/doctor-if-it-were-you-which-would-you-choose-navigating-personal-42318437","doi":"10.1002/dad2.70373","journal":"Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring","n_participants":null,"pmid":"42318437","source_url":"https://pubmed.ncbi.nlm.nih.gov/42318437/","study_design":null,"title":"\u201cDoctor, if it were you, which would you choose?\u201d: Navigating personal preference questions in anti\u2010amyloid immunotherapy selection","title_match":false,"year":2026},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/the-cost-of-alzheimer-drug-treatment-2f85dd17","doi":"10.18103/mra.v14i1.7163","journal":"Medical Research Archives","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.18103/mra.v14i1.7163","study_design":null,"title":"The Cost of Alzheimer Drug Treatment","title_match":false,"year":2025},{"alzhub_score":29,"alzhub_url":"https://alzhub.org/study/the-cost-of-alzheimer-drug-treatment-eb95fab7","doi":"10.5281/zenodo.18531026","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.18531026","study_design":null,"title":"The Cost of Alzheimer Drug Treatment","title_match":false,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/the-cost-of-alzheimer-drug-treatment-11d677d7","doi":"10.5281/zenodo.18531027","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.18531027","study_design":null,"title":"The Cost of Alzheimer Drug Treatment","title_match":false,"year":2026},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/nieuwe-geneesmiddelen-bij-alzheimer-update-69d2f1b5","doi":"10.35351/gebu.nl.2025.11.30","journal":"Geneesmiddelenbulletin","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.35351/gebu.nl.2025.11.30","study_design":null,"title":"Nieuwe geneesmiddelen bij Alzheimer - Update","title_match":false,"year":2025},{"alzhub_score":25,"alzhub_url":"https://alzhub.org/study/netzwerkmetaanalyse-zu-neuen-therapieoptionen-bei-alzheimer-demenz-0b1099e7","doi":"10.1055/a-2523-9611","journal":"Fortschritte der Neurologie \u00b7 Psychiatrie","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1055/a-2523-9611","study_design":null,"title":"Netzwerkmetaanalyse zu neuen Therapieoptionen bei Alzheimer Demenz","title_match":false,"year":2025},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/neue-alzheimer-therapien-vortrag-zu-aria-fur-eine-sichere-mrt-41130241","doi":"10.1055/a-2690-5210","journal":"R\u00f6Fo - Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren","n_participants":null,"pmid":"41130241","source_url":"https://pubmed.ncbi.nlm.nih.gov/41130241/","study_design":null,"title":"Neue Alzheimer-Therapien: Vortrag zu ARIA f\u00fcr eine sichere MRT-Diagnostik","title_match":false,"year":2025},{"alzhub_score":29,"alzhub_url":"https://alzhub.org/study/comprehensive-review-on-alzheimer-disease-causes-risk-factors-837ee353","doi":"10.5281/zenodo.18509182","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.18509182","study_design":null,"title":"Comprehensive Review on Alzheimer Disease: Causes, Risk Factors, Pathology, Mechanisms","title_match":false,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/comprehensive-review-on-alzheimer-disease-causes-risk-factors-54d0f1d7","doi":"10.5281/zenodo.18509183","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.18509183","study_design":null,"title":"Comprehensive Review on Alzheimer Disease: Causes, Risk Factors, Pathology, Mechanisms","title_match":false,"year":2026},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/anticorpos-anti-amiloide-no-tratamento-da-doenca-de-alzheimer-uma-b2f98913","doi":"10.61411/rsc202593118","journal":"Revista Sociedade Cient\u00edfica","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.61411/rsc202593118","study_design":null,"title":"Anticorpos anti-amiloide no tratamento da Doen\u00e7a de Alzheimer: uma revis\u00e3o narrativa","title_match":false,"year":2025},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/interview-interview-zum-thema-neue-alzheimer-therapien-warum-radiolog-41130242","doi":"10.1055/a-2690-4869","journal":"R\u00f6Fo - Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren","n_participants":null,"pmid":"41130242","source_url":"https://pubmed.ncbi.nlm.nih.gov/41130242/","study_design":null,"title":"Interview \u2013 Interview zum Thema: Neue Alzheimer-Therapien: Warum Radiolog:innen ARIA kennen m\u00fcssen","title_match":false,"year":2025},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/biomarcadores-de-laboratorio-en-la-enfermedad-de-alzheimer-avances-520c3a35","doi":"10.24875/kranion.m25000107","journal":"Kranion","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.24875/kranion.m25000107","study_design":null,"title":"Biomarcadores de laboratorio en la enfermedad de Alzheimer: avances recientes e implantaci\u00f3n en un hospital de tercer nivel","title_match":false,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/redefining-alzheimers-disease-through-modern-biotechnology-from-92541794","doi":"10.65035/w1y9ey43","journal":"Journal of medical & health sciences review.","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.65035/w1y9ey43","study_design":null,"title":"REDEFINING ALZHEIMER\u2019S DISEASE THROUGH MODERN BIOTECHNOLOGY; FROM MOLECULAR PATHOGENESIS TO INNOVATIVE THERAPEUTICS AND DIAGNOSTIC FRONTIERS","title_match":false,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/advances-in-immunotherapy-for-alzheimer-s-disease-2020-2023-a-aa1cc3c7","doi":"10.12775/jehs.2025.80.49304","journal":"Journal of Education Health and Sport","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.12775/jehs.2025.80.49304","study_design":null,"title":"Advances in immunotherapy for Alzheimer's Disease 2020-2023 \u2013 a literature review","title_match":false,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/terapia-anti-amiloide-y-enfermedad-cerebrovascular-nuevos-retos-para-7db0e4e9","doi":"10.22379/anc.2188","journal":"Acta neurol\u00f3gica colombiana","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.22379/anc.2188","study_design":null,"title":"Terapia anti \u03b2-amiloide y enfermedad cerebrovascular: nuevos retos para la neurolog\u00eda vascular","title_match":false,"year":2026},{"alzhub_score":42,"alzhub_url":"https://alzhub.org/study/leveraging-digital-twins-for-sample-size-reduction-powering-secondary-41447596","doi":"10.1002/alz70859_101285","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"41447596","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12740155/","study_design":"longitudinal study","title":"Leveraging digital twins for sample size reduction, powering secondary endpoints or subgroups in a simulated TRAILBLAZER\u2010ALZ 2 trial","title_match":false,"year":2025},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/early-alzheimers-disease-mild-cognitive-impairment-or-mild-dementia-40887393","doi":"10.1016/j.tjpad.2025.100362","journal":"The Journal of Prevention of Alzheimer s Disease","n_participants":null,"pmid":"40887393","source_url":"https://pubmed.ncbi.nlm.nih.gov/40887393/","study_design":"narrative review","title":"Early Alzheimer\u2019s disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries","title_match":false,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/donanemab-in-early-symptomatic-alzheimers-disease-results-from-the-41330788","doi":"10.1016/j.tjpad.2025.100446","journal":"The Journal of Prevention of Alzheimer s Disease","n_participants":null,"pmid":"41330788","source_url":"https://pubmed.ncbi.nlm.nih.gov/41330788/","study_design":null,"title":"Donanemab in early symptomatic Alzheimer\u2019s disease: results from the TRAILBLAZER-ALZ 2 long-term extension","title_match":true,"year":2025},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/amyloid-solutions-lecanemab-gantenerumab-and-donanemab-in-the-2abd646d","doi":"10.1186/s41983-025-00968-3","journal":"The Egyptian Journal of Neurology Psychiatry and Neurosurgery","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1186/s41983-025-00968-3","study_design":null,"title":"Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease","title_match":true,"year":2025},{"alzhub_score":55,"alzhub_url":"https://alzhub.org/study/current-advances-and-unmet-needs-in-alzheimer-s-disease-trials-for-40528298","doi":"10.1002/alz.70258","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"40528298","source_url":"https://pubmed.ncbi.nlm.nih.gov/40528298/","study_design":"longitudinal study","title":"Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers","title_match":false,"year":2025},{"alzhub_score":34,"alzhub_url":"https://alzhub.org/study/alzheimers-disease-basics-we-all-should-know-40639927","doi":"10.1080/01616412.2025.2529560","journal":"Neurological Research","n_participants":null,"pmid":"40639927","source_url":"https://pubmed.ncbi.nlm.nih.gov/40639927/","study_design":null,"title":"Alzheimer\u2019s disease basics: we all should know","title_match":false,"year":2025},{"alzhub_score":49,"alzhub_url":"https://alzhub.org/study/a-2025-update-on-treatment-strategies-for-the-alzheimers-disease-40442885","doi":"10.1097/jcma.0000000000001252","journal":"Journal of the Chinese Medical Association","n_participants":null,"pmid":"40442885","source_url":"https://pubmed.ncbi.nlm.nih.gov/40442885/","study_design":null,"title":"A 2025 update on treatment strategies for the Alzheimer\u2019s disease spectrum","title_match":false,"year":2025},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/drug-drug-interaction-signals-between-anti-amyloid-antibodies-and-ba303595","doi":"10.64898/2026.09.08.26362402","journal":"medRxiv (preprint)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.09.08.26362402","study_design":null,"title":"Drug-Drug Interaction Signals Between Anti-Amyloid-\u03b2 Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis","title_match":false,"year":2026},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/the-missing-improvers-tau-pathology-neuroplasticity-and-the-case-for-42594414","doi":"10.1016/j.tjpad.2026.100653","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"42594414","source_url":"https://pubmed.ncbi.nlm.nih.gov/42594414/","study_design":"post-hoc analysis","title":"The missing improvers: Tau pathology, neuroplasticity, and the case for tau-informed patient selection before amyloid immunotherapy","title_match":false,"year":2026},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/equity-and-budget-challenges-associated-with-the-employment-of-anti-42306480","doi":"10.1016/j.jarlif.2026.100076","journal":"JAR life","n_participants":42000,"pmid":"42306480","source_url":"https://pubmed.ncbi.nlm.nih.gov/42306480/","study_design":null,"title":"Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer's Disease in Italy: A scenario analysis","title_match":false,"year":2026},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/implementation-and-service-impact-of-anti-amyloid-therapy-in-a-42019137","doi":"10.1016/j.genhosppsych.2026.04.006","journal":"General hospital psychiatry","n_participants":null,"pmid":"42019137","source_url":"https://pubmed.ncbi.nlm.nih.gov/42019137/","study_design":null,"title":"Implementation and service impact of anti-amyloid therapy in a psychiatry-led dementia care program: Real-world evidence from a Japanese regional dementia center","title_match":false,"year":2026},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/accelerating-alzheimer-s-therapeutic-development-the-past-and-future-37848035","doi":"10.1016/j.cell.2023.09.023","journal":"Cell","n_participants":null,"pmid":"37848035","source_url":"https://pubmed.ncbi.nlm.nih.gov/37848035/","study_design":"clinical trial","title":"Accelerating Alzheimer's therapeutic development: The past and future of clinical trials","title_match":false,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/neurotoxic-soluble-amyloid-oligomers-drive-alzheimer-s-pathogenesis-34198582","doi":"10.3390/ijms22126355","journal":"International journal of molecular sciences","n_participants":null,"pmid":"34198582","source_url":"https://pubmed.ncbi.nlm.nih.gov/34198582/","study_design":null,"title":"Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression","title_match":false,"year":2021},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/detection-and-management-of-amyloid-related-imaging-abnormalities-in-35542992","doi":"10.14283/jpad.2022.21","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"35542992","source_url":"https://pubmed.ncbi.nlm.nih.gov/35542992/","study_design":null,"title":"Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy","title_match":false,"year":2022},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/second-generation-anti-amyloid-monoclonal-antibodies-for-alzheimer-s-39865265","doi":"10.1186/s40035-025-00465-w","journal":"Translational neurodegeneration","n_participants":null,"pmid":"39865265","source_url":"https://pubmed.ncbi.nlm.nih.gov/39865265/","study_design":null,"title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/risk-factors-in-developing-amyloid-related-imaging-abnormalities-aria-38312931","doi":"10.3389/fnins.2024.1326784","journal":"Frontiers in neuroscience","n_participants":null,"pmid":"38312931","source_url":"https://pubmed.ncbi.nlm.nih.gov/38312931/","study_design":null,"title":"Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications","title_match":false,"year":2024},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/donanemab-for-alzheimer-s-disease-a-systematic-review-of-clinical-36611492","doi":"10.3390/healthcare11010032","journal":"Healthcare (Basel, Switzerland)","n_participants":396,"pmid":"36611492","source_url":"https://pubmed.ncbi.nlm.nih.gov/36611492/","study_design":"systematic review","title":"Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials","title_match":true,"year":2022},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/donanemab-population-pharmacokinetics-amyloid-plaque-reduction-and-36805552","doi":"10.1002/cpt.2875","journal":"Clinical pharmacology and therapeutics","n_participants":null,"pmid":"36805552","source_url":"https://pubmed.ncbi.nlm.nih.gov/36805552/","study_design":null,"title":"Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease","title_match":true,"year":2023},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/amyloid-beta-antibody-binding-to-cerebral-amyloid-angiopathy-fibrils-38740836","doi":"10.1038/s41598-024-61691-2","journal":"Scientific reports","n_participants":null,"pmid":"38740836","source_url":"https://pubmed.ncbi.nlm.nih.gov/38740836/","study_design":null,"title":"Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/alzheimer-disease-anti-amyloid-immunotherapies-imaging-39179297","doi":"10.3174/ajnr.a8469","journal":"AJNR. American journal of neuroradiology","n_participants":null,"pmid":"39179297","source_url":"https://pubmed.ncbi.nlm.nih.gov/39179297/","study_design":null,"title":"Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities","title_match":false,"year":2025},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/critical-assessment-of-anti-amyloid-monoclonal-antibodies-effects-in-39468148","doi":"10.1038/s41598-024-75204-8","journal":"Scientific reports","n_participants":null,"pmid":"39468148","source_url":"https://pubmed.ncbi.nlm.nih.gov/39468148/","study_design":"systematic review","title":"Critical assessment of anti-amyloid-\u03b2 monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness","title_match":false,"year":2024},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/implications-of-the-approval-of-lecanemab-for-alzheimer-disease-37295957","doi":"10.1212/wnl.0000000000207438","journal":"Neurology","n_participants":null,"pmid":"37295957","source_url":"https://pubmed.ncbi.nlm.nih.gov/37295957/","study_design":"clinical trial","title":"Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?","title_match":false,"year":2023},{"alzhub_score":84,"alzhub_url":"https://alzhub.org/study/comparative-efficacy-and-safety-of-monoclonal-antibodies-for-38429615","doi":"10.1007/s40263-024-01067-2","journal":"CNS drugs","n_participants":21087,"pmid":"38429615","source_url":"https://pubmed.ncbi.nlm.nih.gov/38429615/","study_design":"meta-analysis","title":"Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis","title_match":false,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-for-alzheimer-s-disease-evidence-41003140","doi":"10.3390/jpm15090437","journal":"Journal of personalized medicine","n_participants":null,"pmid":"41003140","source_url":"https://pubmed.ncbi.nlm.nih.gov/41003140/","study_design":null,"title":"Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection","title_match":false,"year":2025},{"alzhub_score":88,"alzhub_url":"https://alzhub.org/study/trailblazer-alz-4-a-phase-3-trial-comparing-donanemab-with-aducanumab-40390253","doi":"10.1002/alz.70293","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":148,"pmid":"40390253","source_url":"https://pubmed.ncbi.nlm.nih.gov/40390253/","study_design":"clinical trial","title":"TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-in-the-era-of-anti-amyloid-beta-39109501","doi":"10.3348/kjr.2024.0105","journal":"Korean journal of radiology","n_participants":null,"pmid":"39109501","source_url":"https://pubmed.ncbi.nlm.nih.gov/39109501/","study_design":null,"title":"Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer's Disease: Recent Updates on Clinical and Imaging Features and MRI Monitoring","title_match":false,"year":2024},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/re-evaluation-of-the-efficacy-and-safety-of-anti-a-monoclonal-40308765","doi":"10.3389/fphar.2025.1599048","journal":"Frontiers in pharmacology","n_participants":null,"pmid":"40308765","source_url":"https://pubmed.ncbi.nlm.nih.gov/40308765/","study_design":"meta-analysis","title":"Re-evaluation of the efficacy and safety of anti-A\u03b2 monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's disease","title_match":true,"year":2025},{"alzhub_score":67,"alzhub_url":"https://alzhub.org/study/application-of-meta-analysis-to-evaluate-relationships-among-aria-e-35320578","doi":"10.1007/s43441-022-00390-4","journal":"Therapeutic innovation & regulatory science","n_participants":null,"pmid":"35320578","source_url":"https://pubmed.ncbi.nlm.nih.gov/35320578/","study_design":"meta-analysis","title":"Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease","title_match":false,"year":2022},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/the-efficacy-and-safety-of-anti-amyloid-monoclonal-antibody-versus-40316479","doi":"10.1016/j.tjpad.2025.100195","journal":"The journal of prevention of Alzheimer's disease","n_participants":8010,"pmid":"40316479","source_url":"https://pubmed.ncbi.nlm.nih.gov/40316479/","study_design":"randomized controlled trial","title":"The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/recent-advances-in-antibody-therapy-for-alzheimer-s-disease-focus-on-40650049","doi":"10.3390/ijms26136271","journal":"International journal of molecular sciences","n_participants":null,"pmid":"40650049","source_url":"https://pubmed.ncbi.nlm.nih.gov/40650049/","study_design":null,"title":"Recent Advances in Antibody Therapy for Alzheimer's Disease: Focus on Bispecific Antibodies","title_match":false,"year":2025},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/a-systematic-review-of-the-efficacy-and-safety-of-anti-amyloid-40621323","doi":"10.7759/cureus.85377","journal":"Cureus","n_participants":null,"pmid":"40621323","source_url":"https://pubmed.ncbi.nlm.nih.gov/40621323/","study_design":"systematic review","title":"A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer's Disease","title_match":false,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/quantitative-systems-pharmacology-based-exploration-of-relevant-anti-38774587","doi":"10.1002/trc2.12474","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":null,"pmid":"38774587","source_url":"https://pubmed.ncbi.nlm.nih.gov/38774587/","study_design":null,"title":"Quantitative systems pharmacology-based exploration of relevant anti-amyloid therapy challenges in clinical practice","title_match":false,"year":2024},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/anti-amyloid-therapies-and-the-transformation-of-alzheimer-s-care-41732200","doi":"10.1016/j.lanepe.2026.101609","journal":"The Lancet regional health. Europe","n_participants":null,"pmid":"41732200","source_url":"https://pubmed.ncbi.nlm.nih.gov/41732200/","study_design":null,"title":"Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline","title_match":false,"year":2026},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/data-driven-modeling-of-amyloid-targeted-antibodies-for-alzheimer-s-41271757","doi":"10.1038/s41540-025-00610-1","journal":"NPJ systems biology and applications","n_participants":null,"pmid":"41271757","source_url":"https://pubmed.ncbi.nlm.nih.gov/41271757/","study_design":null,"title":"Data-driven modeling of amyloid-\u03b2 targeted antibodies for Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/review-of-anti-amyloid-beta-a-monoclonal-antibodies-for-the-treatment-40940304","doi":"10.1080/17512433.2025.2556122","journal":"Expert review of clinical pharmacology","n_participants":null,"pmid":"40940304","source_url":"https://pubmed.ncbi.nlm.nih.gov/40940304/","study_design":null,"title":"Review of anti-amyloid-beta (A\u03b2) monoclonal antibodies for the treatment of Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":79,"alzhub_url":"https://alzhub.org/study/efficacy-and-apoe-4-stratified-risk-of-donanemab-in-alzheimer-s-40692324","doi":"10.1177/13872877251361044","journal":"Journal of Alzheimer's disease : JAD","n_participants":2054,"pmid":"40692324","source_url":"https://pubmed.ncbi.nlm.nih.gov/40692324/","study_design":"systematic review","title":"Efficacy and APOE \u03b54-stratified risk of donanemab in Alzheimer's disease: A systematic review and meta-analysis of randomized clinical trials","title_match":true,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/recalibrating-the-risk-benefit-profiles-of-lecanemab-and-donanemab-38701151","doi":"10.3233/jad-240171","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"38701151","source_url":"https://pubmed.ncbi.nlm.nih.gov/38701151/","study_design":null,"title":"Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-\u03b242","title_match":true,"year":2024},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/fda-approved-passive-immunization-treatments-against-a-in-alzheimer-s-41596530","doi":"10.3390/ijms27020883","journal":"International journal of molecular sciences","n_participants":null,"pmid":"41596530","source_url":"https://pubmed.ncbi.nlm.nih.gov/41596530/","study_design":null,"title":"FDA-Approved Passive Immunization Treatments Against A\u03b2 in Alzheimer's Disease: Where Are We Now?","title_match":false,"year":2026},{"alzhub_score":81,"alzhub_url":"https://alzhub.org/study/influence-of-patient-characteristics-on-efficacy-and-safety-of-anti-41352683","doi":"10.1016/j.arr.2025.102981","journal":"Ageing research reviews","n_participants":5633,"pmid":"41352683","source_url":"https://pubmed.ncbi.nlm.nih.gov/41352683/","study_design":"systematic review","title":"Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysis","title_match":false,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/advances-of-therapeutic-strategies-for-alzheimer-s-disease-41107537","doi":"10.1007/s00415-025-13456-8","journal":"Journal of neurology","n_participants":null,"pmid":"41107537","source_url":"https://pubmed.ncbi.nlm.nih.gov/41107537/","study_design":null,"title":"Advances of therapeutic strategies for Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-in-the-context-of-41042497","doi":"10.1007/s40266-025-01253-x","journal":"Drugs & aging","n_participants":null,"pmid":"41042497","source_url":"https://pubmed.ncbi.nlm.nih.gov/41042497/","study_design":null,"title":"Amyloid-related Imaging Abnormalities (ARIA) in the Context of Alzheimer's Disease and Amyloid-targeting Therapies: An Introduction for Advanced Practice Providers","title_match":false,"year":2025},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/balancing-benefit-and-risk-in-early-alzheimer-s-disease-the-european-41852829","doi":"10.1016/j.lanepe.2026.101644","journal":"The Lancet regional health. Europe","n_participants":null,"pmid":"41852829","source_url":"https://pubmed.ncbi.nlm.nih.gov/41852829/","study_design":null,"title":"Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab","title_match":true,"year":2026},{"alzhub_score":91,"alzhub_url":"https://alzhub.org/study/donanemab-in-preclinical-alzheimer-s-disease-screening-and-baseline-40955720","doi":"10.1002/alz.70662","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":63124,"pmid":"40955720","source_url":"https://pubmed.ncbi.nlm.nih.gov/40955720/","study_design":"longitudinal study","title":"Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3","title_match":true,"year":2025},{"alzhub_score":75,"alzhub_url":"https://alzhub.org/study/donanemab-treatment-effect-by-baseline-tau-burden-and-disease-42273802","doi":"10.1002/alz.71577","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"42273802","source_url":"https://pubmed.ncbi.nlm.nih.gov/42273802/","study_design":null,"title":"Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial","title_match":true,"year":2026},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/donanemab-exposure-and-efficacy-relationship-using-modeling-in-37388759","doi":"10.1002/trc2.12404","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":null,"pmid":"37388759","source_url":"https://pubmed.ncbi.nlm.nih.gov/37388759/","study_design":"clinical trial","title":"Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease","title_match":true,"year":2023},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/real-world-implementation-of-lecanemab-and-donanemab-in-an-italian-41857623","doi":"10.1186/s13195-026-02015-6","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"41857623","source_url":"https://pubmed.ncbi.nlm.nih.gov/41857623/","study_design":"cohort study","title":"Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience","title_match":true,"year":2026},{"alzhub_score":80,"alzhub_url":"https://alzhub.org/study/donanemab-ly3002813-phase-1b-study-in-alzheimer-s-disease-rapid-and-34585215","doi":"10.14283/jpad.2021.56","journal":"The journal of prevention of Alzheimer's disease","n_participants":18,"pmid":"34585215","source_url":"https://pubmed.ncbi.nlm.nih.gov/34585215/","study_design":null,"title":"Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging","title_match":true,"year":2021},{"alzhub_score":55,"alzhub_url":"https://alzhub.org/study/serial-amyloid-pet-demonstrates-marked-reduction-in-amyloid-burden-42507054","doi":"10.1007/s11604-026-02054-x","journal":"Japanese journal of radiology","n_participants":12,"pmid":"42507054","source_url":"https://pubmed.ncbi.nlm.nih.gov/42507054/","study_design":null,"title":"Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study","title_match":true,"year":2026},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/alzheimer-s-disease-treatment-challenges-for-the-future-40739944","doi":"10.1111/jnc.70176","journal":"Journal of neurochemistry","n_participants":null,"pmid":"40739944","source_url":"https://pubmed.ncbi.nlm.nih.gov/40739944/","study_design":null,"title":"Alzheimer's Disease: Treatment Challenges for the Future","title_match":false,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/passive-anti-amyloid-immunotherapy-in-alzheimer-s-disease-39549715","doi":"10.1016/s0140-6736(24)01883-x","journal":"Lancet (London, England)","n_participants":null,"pmid":"39549715","source_url":"https://pubmed.ncbi.nlm.nih.gov/39549715/","study_design":null,"title":"Passive anti-amyloid \u03b2 immunotherapy in Alzheimer's disease-opportunities and challenges","title_match":false,"year":2024},{"alzhub_score":61,"alzhub_url":"https://alzhub.org/study/eligibility-for-lecanemab-and-donanemab-in-korea-under-appropriate-41225766","doi":"10.1002/alz.70875","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":2726,"pmid":"41225766","source_url":"https://pubmed.ncbi.nlm.nih.gov/41225766/","study_design":null,"title":"Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/treatment-of-alzheimer-disease-39620846","doi":"10.1212/con.0000000000001503","journal":"Continuum (Minneapolis, Minn.)","n_participants":null,"pmid":"39620846","source_url":"https://pubmed.ncbi.nlm.nih.gov/39620846/","study_design":null,"title":"Treatment of Alzheimer Disease","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/anti-amyloid-therapies-for-alzheimer-s-disease-and-the-amyloid-37833948","doi":"10.3390/ijms241914499","journal":"International journal of molecular sciences","n_participants":null,"pmid":"37833948","source_url":"https://pubmed.ncbi.nlm.nih.gov/37833948/","study_design":null,"title":"Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis","title_match":false,"year":2023},{"alzhub_score":82,"alzhub_url":"https://alzhub.org/study/comparative-efficacy-tolerability-and-acceptability-of-donanemab-38253184","doi":"10.1016/j.arr.2024.102203","journal":"Ageing research reviews","n_participants":6547,"pmid":"38253184","source_url":"https://pubmed.ncbi.nlm.nih.gov/38253184/","study_design":"meta-analysis","title":"Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis","title_match":true,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-antibodies-and-anti-tau-therapies-for-alzheimer-s-38945936","doi":"10.1248/cpb.c24-00069","journal":"Chemical & pharmaceutical bulletin","n_participants":null,"pmid":"38945936","source_url":"https://pubmed.ncbi.nlm.nih.gov/38945936/","study_design":"clinical trial","title":"Anti-amyloid-\u03b2 Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives","title_match":false,"year":2024},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/overview-of-alzheimer-s-disease-neuroimaging-initiative-and-future-39711072","doi":"10.1002/alz.14321","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"39711072","source_url":"https://pubmed.ncbi.nlm.nih.gov/39711072/","study_design":null,"title":"Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/donanemab-the-dawn-of-disease-modifying-treatment-for-alzheimer-s-40550741","doi":"10.1177/10398562251355157","journal":"Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists","n_participants":null,"pmid":"40550741","source_url":"https://pubmed.ncbi.nlm.nih.gov/40550741/","study_design":null,"title":"Donanemab: The dawn of disease-modifying treatment for Alzheimer's disease in Australia","title_match":true,"year":2025},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/comparisons-of-efficacy-and-safety-of-immunotherapies-for-alzheimer-s-40473116","doi":"10.1016/j.clinme.2025.100336","journal":"Clinical medicine (London, England)","n_participants":null,"pmid":"40473116","source_url":"https://pubmed.ncbi.nlm.nih.gov/40473116/","study_design":"meta-analysis","title":"Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trials","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/maximizing-the-benefit-and-managing-the-risk-of-anti-amyloid-40118715","doi":"10.1016/j.neurot.2025.e00570","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","n_participants":null,"pmid":"40118715","source_url":"https://pubmed.ncbi.nlm.nih.gov/40118715/","study_design":null,"title":"Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/safety-of-switching-from-lecanemab-to-donanemab-in-20-consecutive-40708311","doi":"10.1177/13872877251361051","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"40708311","source_url":"https://pubmed.ncbi.nlm.nih.gov/40708311/","study_design":null,"title":"Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/donanemab-another-anti-alzheimer-s-drug-with-risk-and-uncertain-38830549","doi":"10.1016/j.arr.2024.102348","journal":"Ageing research reviews","n_participants":null,"pmid":"38830549","source_url":"https://pubmed.ncbi.nlm.nih.gov/38830549/","study_design":null,"title":"Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit","title_match":true,"year":2024},{"alzhub_score":82,"alzhub_url":"https://alzhub.org/study/comparative-efficacy-tolerability-and-acceptability-of-aducanumab-40386876","doi":"10.1177/02698811251340901","journal":"Journal of psychopharmacology (Oxford, England)","n_participants":6918,"pmid":"40386876","source_url":"https://pubmed.ncbi.nlm.nih.gov/40386876/","study_design":"meta-analysis","title":"Comparative efficacy, tolerability, and acceptability of aducanumab, lecanemab, and donanemab with repetitive transcranial magnetic stimulation on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/donanemab-not-two-without-a-third-37831471","doi":"10.17219/acem/172673","journal":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","n_participants":null,"pmid":"37831471","source_url":"https://pubmed.ncbi.nlm.nih.gov/37831471/","study_design":null,"title":"Donanemab: Not two without a third","title_match":true,"year":2023},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/identifying-genetic-risk-for-amyloid-related-imaging-abnormalities-38165303","doi":"10.1212/wnl.0000000000208096","journal":"Neurology","n_participants":null,"pmid":"38165303","source_url":"https://pubmed.ncbi.nlm.nih.gov/38165303/","study_design":null,"title":"Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities","title_match":false,"year":2024},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/how-donanemab-data-address-the-coverage-with-evidence-development-38323738","doi":"10.1002/alz.13700","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"38323738","source_url":"https://pubmed.ncbi.nlm.nih.gov/38323738/","study_design":null,"title":"How donanemab data address the coverage with evidence development questions","title_match":true,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/optimal-anti-amyloid-beta-therapy-for-alzheimer-s-disease-via-a-36054214","doi":"10.1371/journal.pcbi.1010481","journal":"PLoS computational biology","n_participants":null,"pmid":"36054214","source_url":"https://pubmed.ncbi.nlm.nih.gov/36054214/","study_design":null,"title":"Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model","title_match":false,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/pharmacological-interventions-in-dementia-41047647","doi":"10.11477/mf.030126030530050943","journal":"No shinkei geka. Neurological surgery","n_participants":null,"pmid":"41047647","source_url":"https://pubmed.ncbi.nlm.nih.gov/41047647/","study_design":null,"title":"[Pharmacological Interventions in Dementia]","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/pharmacokinetic-evaluation-of-donanemab-for-the-treatment-of-38758223","doi":"10.1080/17425255.2024.2357637","journal":"Expert opinion on drug metabolism & toxicology","n_participants":null,"pmid":"38758223","source_url":"https://pubmed.ncbi.nlm.nih.gov/38758223/","study_design":null,"title":"Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's","title_match":true,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/the-tale-of-donanemab-god-is-in-the-details-40899945","doi":"10.1177/13872877251371240","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"40899945","source_url":"https://pubmed.ncbi.nlm.nih.gov/40899945/","study_design":null,"title":"The tale of donanemab: God is in the details","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/comparing-clinical-effect-sizes-of-souvenaidtm-lecanemab-and-41428477","doi":"10.1177/13872877251406221","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"41428477","source_url":"https://pubmed.ncbi.nlm.nih.gov/41428477/","study_design":null,"title":"Comparing clinical effect sizes of SouvenaidTM, lecanemab, and donanemab in early Alzheimer's disease","title_match":true,"year":2026},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/review-of-donanemab-and-lecanemab-in-mild-dementia-stage-of-alzheimer-41966037","doi":"10.4140/tcp.n.2026.98","journal":"The Senior care pharmacist","n_participants":null,"pmid":"41966037","source_url":"https://pubmed.ncbi.nlm.nih.gov/41966037/","study_design":null,"title":"Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and Challenges","title_match":true,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/therapeutic-news-in-alzheimer-s-disease-soon-a-disease-modifying-35489824","doi":"10.1016/j.neurol.2022.02.456","journal":"Revue neurologique","n_participants":null,"pmid":"35489824","source_url":"https://pubmed.ncbi.nlm.nih.gov/35489824/","study_design":null,"title":"Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?","title_match":false,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/alzheimer-s-amyloid-hypothesis-and-antibody-therapy-melting-glaciers-38612701","doi":"10.3390/ijms25073892","journal":"International journal of molecular sciences","n_participants":null,"pmid":"38612701","source_url":"https://pubmed.ncbi.nlm.nih.gov/38612701/","study_design":null,"title":"Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-antibody-therapy-for-alzheimer-s-disease-39370836","doi":"10.11477/mf.1416202747","journal":"Brain and nerve = Shinkei kenkyu no shinpo","n_participants":null,"pmid":"39370836","source_url":"https://pubmed.ncbi.nlm.nih.gov/39370836/","study_design":"clinical trial","title":"[Anti-Amyloid Antibody Therapy for Alzheimer's Disease]","title_match":false,"year":2024},{"alzhub_score":69,"alzhub_url":"https://alzhub.org/study/the-effect-of-modified-donanemab-titration-on-amyloid-related-imaging-40619285","doi":"10.1016/j.tjpad.2025.100266","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"40619285","source_url":"https://pubmed.ncbi.nlm.nih.gov/40619285/","study_design":null,"title":"The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6","title_match":true,"year":2025},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/donanemab-for-alzheimer-s-disease-from-preclinical-research-to-the-40790925","doi":"10.1080/14737175.2025.2546868","journal":"Expert review of neurotherapeutics","n_participants":null,"pmid":"40790925","source_url":"https://pubmed.ncbi.nlm.nih.gov/40790925/","study_design":"systematic review","title":"Donanemab for Alzheimer's disease: from preclinical research to the clinical application","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/antibody-therapy-in-alzheimer-s-disease-42714614","doi":"10.1007/s00391-026-02640-8","journal":"Zeitschrift fur Gerontologie und Geriatrie","n_participants":null,"pmid":"42714614","source_url":"https://pubmed.ncbi.nlm.nih.gov/42714614/","study_design":null,"title":"[Antibody therapy in Alzheimer's disease]","title_match":false,"year":2026},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/from-bench-to-bedside-cutting-edge-and-emerging-therapies-for-40993929","doi":"10.2174/0118715249388723250910140541","journal":"Central nervous system agents in medicinal chemistry","n_participants":null,"pmid":"40993929","source_url":"https://pubmed.ncbi.nlm.nih.gov/40993929/","study_design":null,"title":"From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's Disease","title_match":false,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/passive-alzheimer-s-immunotherapy-a-promising-or-uncertain-option-37414156","doi":"10.1016/j.arr.2023.101996","journal":"Ageing research reviews","n_participants":null,"pmid":"37414156","source_url":"https://pubmed.ncbi.nlm.nih.gov/37414156/","study_design":null,"title":"Passive Alzheimer's immunotherapy: A promising or uncertain option?","title_match":false,"year":2023},{"alzhub_score":63,"alzhub_url":"https://alzhub.org/study/real-world-evidence-for-amyloid-targeted-therapies-lecanemab-and-42661728","doi":"10.1002/dad2.70404","journal":"Alzheimer's & dementia (Amsterdam, Netherlands)","n_participants":89,"pmid":"42661728","source_url":"https://pubmed.ncbi.nlm.nih.gov/42661728/","study_design":null,"title":"Real-world evidence for amyloid-targeted therapies: Lecanemab and donanemab","title_match":true,"year":2026},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/nanobody-therapeutics-in-alzheimer-s-disease-from-molecular-41562774","doi":"10.3390/antib15010001","journal":"Antibodies (Basel, Switzerland)","n_participants":null,"pmid":"41562774","source_url":"https://pubmed.ncbi.nlm.nih.gov/41562774/","study_design":null,"title":"Nanobody Therapeutics in Alzheimer's Disease: From Molecular Mechanisms to Translational Approaches","title_match":false,"year":2025},{"alzhub_score":54,"alzhub_url":"https://alzhub.org/study/potential-impact-of-unblinding-on-observed-treatment-effects-in-38380503","doi":"10.1002/alz.13690","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"38380503","source_url":"https://pubmed.ncbi.nlm.nih.gov/38380503/","study_design":"clinical trial","title":"Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials","title_match":false,"year":2024},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/quantitative-systems-pharmacology-analysis-of-amyloid-aggregation-and-a02492d7","doi":"10.21203/rs.3.rs-10570608/v1","journal":"Research Square","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.21203/rs.3.rs-10570608/v1","study_design":"clinical trial","title":"Quantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer\u2019s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 Treatment","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/when-is-amyloid-really-cleared-substantial-discordance-between-fc03ab7d","doi":"10.64898/2026.10.03.26364642","journal":"medRxiv","n_participants":15,"pmid":null,"source_url":"https://doi.org/10.64898/2026.10.03.26364642","study_design":null,"title":"When Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantitation and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy","title_match":false,"year":2026},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/data-driven-modeling-of-amyloid-beta-targeted-antibodies-for-32628a51","doi":"10.21203/rs.3.rs-6316455/v1","journal":"NPJ systems biology and applications","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.21203/rs.3.rs-6316455/v1","study_design":null,"title":"Data-Driven Modeling of Amyloid-beta Targeted Antibodies for Alzheimer\u2019s Disease","title_match":false,"year":2025},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/a-transferable-health-economic-evaluation-framework-for-alzheimers-e890aa4f","doi":"10.21203/rs.3.rs-9602832/v1","journal":"Research Square","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.21203/rs.3.rs-9602832/v1","study_design":null,"title":"A Transferable Health Economic Evaluation Framework for Alzheimer\u2019s Disease-Modifying Therapies","title_match":false,"year":2026},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/anti-amyloid-therapies-for-alzheimers-disease-progress-pitfalls-and-41096797","doi":"10.3390/ijms26199529","journal":"International Journal of Molecular Sciences","n_participants":null,"pmid":"41096797","source_url":"https://pubmed.ncbi.nlm.nih.gov/41096797/","study_design":null,"title":"Anti-Amyloid Therapies for Alzheimer\u2019s Disease: Progress, Pitfalls, and the Path Ahead","title_match":false,"year":2025},{"alzhub_score":62,"alzhub_url":"https://alzhub.org/study/trailblazer-alz-4-topline-study-results-directly-comparing-donanemab-7521651f","doi":"10.1192/bjo.2023.227","journal":"BJPsych Open","n_participants":148,"pmid":null,"source_url":"https://doi.org/10.1192/bjo.2023.227","study_design":"clinical trial","title":"TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease","title_match":true,"year":2023},{"alzhub_score":64,"alzhub_url":"https://alzhub.org/study/donanemab-in-early-symptomatic-alzheimers-disease-efficacy-and-safety-3d9d0576","doi":"10.1002/alz.082733","journal":"Alzheimer s & Dementia","n_participants":1182,"pmid":null,"source_url":"https://doi.org/10.1002/alz.082733","study_design":null,"title":"Donanemab in Early Symptomatic Alzheimer\u2019s Disease: Efficacy and Safety in TRAILBLAZER\u2010ALZ 2, a Phase 3 Randomized Clinical Trial","title_match":true,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/donanemab-ly3002813-doseescalation-study-in-alzheimer-s-disease-3ffcda2a","doi":"10.1002/trc2.12112","journal":"Alzheimer's & Dementia: Translational Research & Clinical Interventions","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1002/trc2.12112","study_design":null,"title":"Donanemab (LY3002813) dose\u2010escalation study in Alzheimer's disease","title_match":true,"year":2021},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/donanemab-leads-to-less-decline-in-early-alzheimer-s-disease-38d83515","doi":"10.1002/pu.30739","journal":"The Brown University Psychopharmacology Update","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1002/pu.30739","study_design":"clinical trial","title":"Donanemab leads to less decline in early Alzheimer's disease","title_match":true,"year":2021}]}